As of Friday close, Reata Pharmaceuticals Inc.’s (NASDAQ:RETA) stock was up $0.26, moving up 0.15 percent to $169.26. The average number of shares traded per day over the past five days has been 899,120 shares. 1 time new highs have been achieved over the past 5 days, with a $1.78 gain in that time frame. In the last twenty days, the average volume was 1,600,845, while in the previous 50 days, it was 1,051,346.
Since last month, RETA stock rose 53.72%. Shares of the company fell to $104.50 on 07/26/23, the lowest level in the past month. A 52-week high of $169.75 was reached on 08/14/23 after having rallying from a 52-week low of $19.02. Since the beginning of this year, RETA’s stock price has risen by 345.54% or $131.27, and marked a new high 32 times. However, the stock has declined by -0.29% since its 52-week high.
RETA stock investors should be aware that Reata Pharmaceuticals Inc. (RETA) stock had its last reported insider trading activity 3 days ago on Aug 16. Soni Manmeet Singh, the COO, CFO and President of the company, disposed of 1,755 shares for $168.41 on Aug 16. It resulted in a $295,566 divestment by the insider. Meyer Colin John sold 596 shares at an average price of $168.74 on Aug 16. The insider now owns 81,633 shares following the transaction. On Aug 16, Chief Legal Officer WORTLEY MICHAEL D sold 398 shares at $168.76 apiece. The transaction was valued at $67,167.
Valuation Metrics
The stock’s beta is 1.41. Besides these, the trailing price-to-sales (P/S) ratio of 274.06, the price-to-book (PB) ratio of 72.96.
Financial Health
In the three months ended June 29, Reata Pharmaceuticals Inc.’s quick ratio stood at 3.20, while its current ratio was 3.20, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.84, and the total debt-to-equity ratio was 0.84. On the profitability front, the trailing twelve-month gross margin is 96.40% percent. Based on annual data, RETA earned $280.25 million in gross profit and brought in $2.22 million in revenue.
In Reata Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $73.13 million against cash and short-term investments of $281.37 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. RETA’s revenue rose 96.66% to $0.2 million during the quarter, while net income inched up to $22.75 million. While analysts expected Reata Pharmaceuticals Inc. to report -$2.88 quarterly earnings, the actual figure was $4.65 per share, beating the consensus estimate by 261.50%. During the quarter, the company generated -$94.54 million in EBITDA. The liabilities of Reata Pharmaceuticals Inc. were 415.3 million at the end of its most recent quarter ended June 29, and its total debt was $166.0 million. The value of shareholders’ equity is $38.15 million.
Technical Picture
This quick technical analysis looks at Reata Pharmaceuticals Inc.’s (RETA) price momentum. With a historical volatility rate of 5.36%, the RSI 9-day stood at 87.15% on 18 August.
With respect to its five-day moving average, the current Reata Pharmaceuticals Inc. price is up by +1.06% percent or $1.78. At present, RETA shares trade +52.68% above its 20-day simple moving average and +91.19% percent above its 100-day simple moving average. However, the stock is currently trading approximately +80.81% above its SMA50 and +425.65% above its SMA200.
Stochastic coefficient K was 86.78% and Stochastic coefficient D was 90.73%, while ATR was 2.76. Given the Stochastic reading of 88.94% for the 14-day period, the RSI (14) reading has been calculated as 84.26%. As of today, the MACD Oscillator reading stands at 0.83, while the 14-day reading stands at 1.46.
Analyst Ratings
TD Cowen launched its rating on Reata Pharmaceuticals Inc. (NASDAQ: RETA) to an Outperform in a note to investors on July 06, 2023. Reata Pharmaceuticals Inc. (RETA) has been rated Hold by analysts. According to 0 brokerage firms, RETA is a sell, and 10 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Reata Pharmaceuticals Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $172.50, the current consensus forecast for the stock is $172.00 – $173.00. Based on these forecasts, analysts predict Reata Pharmaceuticals Inc. (RETA) will achieve an average price target of $172.45.
